Chemotherapy, a Trusty Weapon Against Cancer, Falls Out of Favor
The Wall Street Journal - February 01, 2018
Should women with breast cancer get chemotherapy? Research led by Joseph Sparano, M.D., may help oncologists refine their use of chemotherapy and hormone therapy for women with early-stage disease. Dr. Sparano is vice chairman of medical oncology at Montefiore Einstein Center for Cancer Care and associate director of clinical research at the NCI-designated Albert Einstein Cancer Center.
Blood Test May Help Predict Which Breast Cancers Will Recur
Associated Press - December 12, 2017
Dr. Joseph Sparano found that a blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared. Dr. Sparano is vice chairman of medical oncology at Montefiore Einstein Center for Cancer Care and associate director of clinical research at the NCI-designated Albert Einstein Cancer Center.
NBC Nightly News interviews Joseph Sparano, M.D., about his study that found just being overweight increases the risk of breast cancer recurrence. Dr. Sparano notes that the link between obesity and cancer remains regardless of treatment and that reducing weight may reduce risk of recurrence. Dr. Sparano is professor of medicine and of obstetrics & gynecology and women's health at Einstein and chief of the section of breast medical oncology at Montefiore Einstein Center for Cancer Care.
More coverage on this story
ABCNews.com
CBSNews.com
CBC News (Canada)
Reuters
Time.com
Pittsburgh Post-Gazette
UPI
ABC (Spain)
El Mundo (Spain)
August 28, 2012
The Los Angeles Times interviews Joseph Sparano, M.D., in an article on the growing evidence linking obesity with increased risk of cancer and mortality. Researchers estimate that approximately 14% of cancer deaths in men and 20% in women are due to individuals being overweight or obese. Dr. Sparano comments on the results of the Women’s Intervention Nutrition Study, which found that the risk of breast cancer recurrence dropped by 25% in patients who stuck to a low-fat diet. He notes that if those results were due to a drug rather than a diet, it would be considered an effective treatment. Dr. Sparano is professor of medicine and of obstetrics & gynecology and women's health and associate chair of oncology at Montefiore Medical Center.
March 7, 2011
CNN.com interviews Dr. Joseph Sparano about the FDA's controversial decision to phase out the drug Avastin as a treatment for metastatic breast cancer. The FDA says Avastin's side effects outweigh potential benefits for those with metastatic cancer. Dr. Sparano notes the announcement still allows doctors to prescribe Avastin for metastatic breast cancer, but only for those who can afford it, rather than those who medically could benefit from it. The FDA announcement does not affect Avastin's status as an approved therapy for lung, kidney, colorectal and brain cancers. Dr. Sparano is professor of medicine (oncology) and of obstetrics & gynecology and women's health.
December 17, 2010
Bloomberg highlights research by Joseph Sparano, M.D., that found obese women who have a type of breast cancer fueled by estrogen are more likely to die of the disease than their slimmer peers. Dr. Sparano notes that breast cancer patients who are already overweight or obese should make an effort to avoid further weight gain and that they should get nutritional evaluations. Dr. Sparano is professor of medicine and of obstetrics & gynecology and women's health and associate chair of oncology at Montefiore Medical Center.
December 9, 2010